ES2421455T3 - Uso de derivados de rapamicina en vasculopatías - Google Patents

Uso de derivados de rapamicina en vasculopatías

Info

Publication number
ES2421455T3
ES2421455T3 ES08017336T ES08017336T ES2421455T3 ES 2421455 T3 ES2421455 T3 ES 2421455T3 ES 08017336 T ES08017336 T ES 08017336T ES 08017336 T ES08017336 T ES 08017336T ES 2421455 T3 ES2421455 T3 ES 2421455T3
Authority
ES
Spain
Prior art keywords
vasculopathies
rapamycin derivatives
rapamycin
derivatives
enlargement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES08017336T
Other languages
English (en)
Spanish (es)
Inventor
Walter Schuler
Hessel Johannes Schuurmann
Gisbert Weckbecker
Hans-Guenter Zerwes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2421455(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Application granted granted Critical
Publication of ES2421455T3 publication Critical patent/ES2421455T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES08017336T 1996-03-27 1997-03-26 Uso de derivados de rapamicina en vasculopatías Expired - Lifetime ES2421455T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9606452.2A GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds

Publications (1)

Publication Number Publication Date
ES2421455T3 true ES2421455T3 (es) 2013-09-02

Family

ID=10791127

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97915441T Expired - Lifetime ES2184078T3 (es) 1996-03-27 1997-03-26 Uso de derivados de rapamicina en vasculopatias y xenotrasplantes.
ES08017336T Expired - Lifetime ES2421455T3 (es) 1996-03-27 1997-03-26 Uso de derivados de rapamicina en vasculopatías

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES97915441T Expired - Lifetime ES2184078T3 (es) 1996-03-27 1997-03-26 Uso de derivados de rapamicina en vasculopatias y xenotrasplantes.

Country Status (29)

Country Link
US (5) US6384046B1 (enExample)
EP (3) EP2008657B1 (enExample)
JP (2) JP2000507226A (enExample)
KR (2) KR100836971B1 (enExample)
CN (1) CN1124135C (enExample)
AT (1) ATE224194T1 (enExample)
AU (1) AU716514B2 (enExample)
BR (1) BR9708358A (enExample)
CA (1) CA2247275C (enExample)
CY (1) CY2404B1 (enExample)
CZ (1) CZ292483B6 (enExample)
DE (1) DE69715611T2 (enExample)
DK (2) DK0893996T3 (enExample)
ES (2) ES2184078T3 (enExample)
GB (1) GB9606452D0 (enExample)
HU (1) HU226422B1 (enExample)
ID (1) ID17195A (enExample)
IL (1) IL125812A (enExample)
MY (1) MY117798A (enExample)
NO (1) NO316667B1 (enExample)
NZ (1) NZ331463A (enExample)
PL (1) PL187732B1 (enExample)
PT (2) PT893996E (enExample)
RU (1) RU2214247C2 (enExample)
SI (1) SI2008657T1 (enExample)
SK (1) SK284343B6 (enExample)
TR (1) TR199801919T2 (enExample)
WO (1) WO1997035575A1 (enExample)
ZA (1) ZA972719B (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
ATE222502T1 (de) 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
ATE474590T1 (de) 1999-05-10 2010-08-15 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
IL151501A0 (en) 2000-03-15 2003-04-10 Orbus Medical Technologies Inc Coating that promotes endothelial cell adherence
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
EP1709974A3 (en) * 2000-06-16 2006-12-06 Wyeth Method of treating cardiovascular disease using rapamycin
DE60124285T3 (de) 2000-09-29 2011-03-17 Cordis Corp., Miami Lakes Beschichtete medizinische geräte
EP2762140B1 (en) * 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20050255111A1 (en) * 2002-02-22 2005-11-17 Olle Korsgren Use of an inhibitor or antagonist against tissue factor
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
CN1655738A (zh) * 2002-05-20 2005-08-17 奥勃斯医学技术股份有限公司 可植入的药物洗脱医疗装置
US8109987B2 (en) 2003-04-14 2012-02-07 Tryton Medical, Inc. Method of treating a lumenal bifurcation
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
TW200605910A (en) * 2004-04-30 2006-02-16 Orbus Medical Technologies Inc Medical device with coating for capturing genetically-altered cells and methods for using same
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1838288A4 (en) * 2004-12-20 2010-08-04 Ariad Pharma Inc THERAPEUTIC MATERIALS AND METHODS
US20070185150A1 (en) 2005-11-14 2007-08-09 Bedrosian Camille L Therapeutic methods
US20080317814A1 (en) * 2005-11-17 2008-12-25 Access Plus Co., Ltd. Tube for Connecting Marteriovenous and Interposition for Medical Operation
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
CN101557814B (zh) 2006-09-13 2015-05-20 万能医药公司 大环内酯化合物及它们的使用方法
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
CN103480047B (zh) 2007-11-14 2015-02-18 生物传感器国际集团有限公司 自动化涂覆设备和方法
US8921642B2 (en) * 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
US20100086579A1 (en) * 2008-10-03 2010-04-08 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8366763B2 (en) 2009-07-02 2013-02-05 Tryton Medical, Inc. Ostium support for treating vascular bifurcations
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
UA104738C2 (ru) 2011-05-18 2014-03-11 Олег Миколайович Лазаренко Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
BR112016006378A2 (pt) 2013-09-24 2017-08-01 Giner Inc sistema para tratamento de gás de um implante de célula
CA2926719C (en) 2013-10-08 2020-11-24 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
AU2015217349A1 (en) 2014-02-11 2016-09-08 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
RS64482B1 (sr) 2014-04-04 2023-09-29 Ai Therapeutics Inc Inhalaciona formulacija rapamicina za lečenje stanja povezanih sa starenjem
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20190167649A1 (en) 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
US12453624B2 (en) 2016-09-19 2025-10-28 Biotronik Ag Polymer-free drug eluting vascular stents
WO2018093956A1 (en) 2016-11-15 2018-05-24 Giner, Inc. Percutaneous gas diffusion device suitable for use with a subcutaneous implant
JP7118061B2 (ja) 2016-12-22 2022-08-15 バイオトロニック アクチェンゲゼルシャフト 医療装置のための薬剤放出被膜およびその作製方法
JP7199632B2 (ja) 2017-05-04 2023-01-06 ガイナー，インク． 堅牢なインプラント可能なガス送達装置ならびにそれを含む方法、システムおよび装置
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
FI3898637T3 (fi) 2018-12-18 2025-02-24 Novartis Ag Rapamysiinijohdannaisia
EP3927319A1 (en) 2019-02-20 2021-12-29 AI Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2094858C (en) * 1992-04-28 2004-06-15 Robert D. Mitchell Method of treating hyperproliferative vascular disease
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
ES2146741T3 (es) * 1993-12-17 2000-08-16 Novartis Ag Derivados de rapamicina utiles como inmunosupresores.
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
RU2158267C2 (ru) * 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
JP5124431B2 (ja) 2013-01-23
HUP0001267A3 (en) 2002-01-28
US20140187574A1 (en) 2014-07-03
HUP0001267A2 (hu) 2000-11-28
EP0893996B1 (en) 2002-09-18
PT893996E (pt) 2002-12-31
WO1997035575A1 (en) 1997-10-02
CY2404B1 (en) 2004-09-10
KR100836971B1 (ko) 2008-06-10
US20120177690A1 (en) 2012-07-12
PL328659A1 (en) 1999-02-15
GB9606452D0 (en) 1996-06-05
KR20070083654A (ko) 2007-08-24
ES2184078T3 (es) 2003-04-01
SK132798A3 (en) 1999-03-12
EP0893996A1 (en) 1999-02-03
AU2291897A (en) 1997-10-17
NZ331463A (en) 2001-10-26
ID17195A (id) 1997-12-11
JP2000507226A (ja) 2000-06-13
US20020127248A1 (en) 2002-09-12
MY117798A (en) 2004-08-30
CZ292483B6 (cs) 2003-09-17
US20100152105A1 (en) 2010-06-17
HK1018688A1 (en) 1999-12-30
DE69715611D1 (de) 2002-10-24
NO984340D0 (no) 1998-09-18
PL187732B1 (pl) 2004-09-30
EP1149581A2 (en) 2001-10-31
EP2008657A2 (en) 2008-12-31
CN1214631A (zh) 1999-04-21
EP2008657A3 (en) 2009-02-04
ZA972719B (en) 1998-09-28
IL125812A0 (en) 1999-04-11
EP1149581A3 (en) 2003-12-03
JP2009102349A (ja) 2009-05-14
KR20050038656A (ko) 2005-04-27
ATE224194T1 (de) 2002-10-15
AU716514B2 (en) 2000-02-24
US6384046B1 (en) 2002-05-07
BR9708358A (pt) 1999-08-03
DE69715611T2 (de) 2003-05-22
IL125812A (en) 2001-12-23
TR199801919T2 (xx) 1999-02-22
CA2247275A1 (en) 1997-10-02
RU2214247C2 (ru) 2003-10-20
CN1124135C (zh) 2003-10-15
HU226422B1 (en) 2008-12-29
DK0893996T3 (da) 2002-12-09
SK284343B6 (sk) 2005-02-04
PT2008657E (pt) 2013-07-12
CA2247275C (en) 2011-10-11
SI2008657T1 (sl) 2013-07-31
CZ307098A3 (cs) 1999-01-13
DK2008657T3 (da) 2013-07-22
NO316667B1 (no) 2004-03-29
NO984340L (no) 1998-09-18
EP2008657B1 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
ES2421455T3 (es) Uso de derivados de rapamicina en vasculopatías
PT1385551E (pt) Associações antineoplásicas compreendendo cci-779 (derivado de rapamicina) associado a gemcitabina ou fluorouracilo
FR11C0037I1 (enExample)
ES2155531T3 (es) Compuestos de poliaminas para el tratamiento de desordenes vasculares proliferativos.
ES2146774T3 (es) Polimeros de ioneno que contienen aniones biologicamente activos.
BR0311375A (pt) Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
ATE211931T1 (de) Topoisomerase inhibitoren zur restenose- prevention
PT907652E (pt) Compostos e processos imunossupressores
FI20001943L (fi) O-alkyloituja rapamysiinijohdannaisia ja niiden käyttö, erityisesti immunosupressoivina aineina
TR200200821T2 (tr) 5-Beta-sapojenin ve pseudosapojenin türevleri ve bunların bunama tedavisinde kullanımı.
BR9710370A (pt) Composi-Æo antimicrobiana e m-todo pata prepara-Æo da mesma
SE9904377D0 (sv) Pharmaceutical combinations
AR016981A2 (es) Polipeptidos sinteticos
PT892796E (pt) Derivados de isatina como inibidores de acetilcolinesterase e analgesicos
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
ES2064119T3 (es) Nuevos derivados de aminobenzosultam como inhibidores de la lipoxigenasa.
MX9405371A (es) Derivado de naftilo.
HU9701060D0 (en) Pharmaceutical composition for treating cognitive disturbs
ES2196769T3 (es) Uso topico de loperamide para el tratamiento de infecciones microbianas.
ID18301A (id) Metode-metode untuk pencegahan proliferasi seluler dan restenosis
AR026756A1 (es) Nuevas combinaciones terapeuticas (s)-2-bencilamino-metil)-2,3,8,9-tetrahidro-7h-1,4-dioxino[2,3-e]indol-8-ona y neuroleticos para el tratamiento oprevencion de desordenes psicoticos
BRPI0415714A (pt) uso de cci-779, composição farmacêutica e embalagem farmacêutica
BR0317119A (pt) Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina
TR200101346T2 (tr) Rilüzol ve alfa-tokoferol bileşimi
ES2165020T3 (es) Monohidrato de famciclovir.